Literature DB >> 2677234

Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein.

R J Brideau1, R R Walters, M A Stier, M W Wathen.   

Abstract

The cotton rat model of experimental human respiratory syncytial virus (RSV) infection was used to study the efficacy of FG, a novel chimeric glycoprotein which was expressed in insect cells using a baculovirus vector. FG contained the extracellular regions of the F (fusion) and G (attachment) glycoproteins of RSV. Vaccination with FG resulted in induction of neutralizing antibody and was correlated with protection of lung tissue from RSV challenge against both serogroup A and B virus strains. Both crude FG taken from supernatants of insect cells and affinity-purified FG were immunogenic and active against RSV. FG vaccination was effective by three routes of administration, following a single dose, and when administered with different adjuvants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677234     DOI: 10.1099/0022-1317-70-10-2637

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus).

Authors:  Jessica L Grieves; Zhiwei Yin; Russell K Durbin; Joan E Durbin
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

Review 2.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 3.  Respiratory syncytial virus genetic and antigenic diversity.

Authors:  W M Sullender
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

Authors:  J A Nicholas; K L Rubino; M E Levely; E G Adams; P L Collins
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.

Authors:  Tiffany M Turner; Les P Jones; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

6.  Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes.

Authors:  M E Levely; C A Bannow; C W Smith; J A Nicholas
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

7.  Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats.

Authors:  G A Prince; C Capiau; M Deschamps; L Fabry; N Garçon; D Gheysen; J P Prieels; G Thiry; O Van Opstal; D D Porter
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 8.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

9.  Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection.

Authors:  F M Piazza; S A Johnson; M E Darnell; D D Porter; V G Hemming; G A Prince
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Recombinant type 5 adenoviruses expressing bovine parainfluenza virus type 3 glycoproteins protect Sigmodon hispidus cotton rats from bovine parainfluenza virus type 3 infection.

Authors:  M M Breker-Klassen; D Yoo; S K Mittal; S D Sorden; D M Haines; L A Babiuk
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.